Drug
Bcx9930
Bcx9930: highest development phase Phase 2, developed by BioCryst Pharmaceuticals. 4 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BioCryst Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| BCX9930 NCT05741346 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria |
| BCX9930 NCT05162066 | Phase 2 | Complement 3 Glomerulopathy |
| BCX9930 NCT04702568 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria |
| BCX9930 NCT04330534 | Phase 1/2 | Paroxysmal Nocturnal Hemoglobinuria |
Latest
No recent events.
Follow Bcx9930 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.